Improvements in chemotherapy and better ways to stratify patients based upon genetic abnormalities and on initial treatment response measured by minimal residual disease [18–20], together with specific protocols for infants and BCR-ABL positive patients, further improved outcome for ALL patients. Here, ABL1 is linked to acute lymphoblastic leukemia.